bevacizumab,cetuximab
roche,eli lilly
['fire-4']
fire-4 - 20% of ras wt on tissue found to have ras/raf mut on liquid bx, and clinically behaved like ras mut. back-of-envelope calc of $54k for liquid bx of all ras wt (tissue) to break even vs 9 months of inappropriate egfr therapy. liquid bx for all??? #asco23 
Chemo jockey @permanentedocs and weekend warrior.  Tweets are my own, and don't represent medical advice or the position of any affiliated organization.